drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T-cell therapy)
drug_description
Autologous, gene-modified CD19-directed CAR T-cell therapy. Patient T cells are engineered ex vivo to express an anti-CD19 CAR and, after infusion, selectively recognize and eliminate CD19+ B-lineage cells to deplete autoreactive B cells and suppress humoral autoimmunity in moderate to severe SLE.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
relmacabtagene autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified ex vivo to express an anti-CD19 chimeric antigen receptor; after infusion, the CAR T cells recognize CD19 on B-lineage cells and eliminate them via CAR-mediated cytotoxicity, depleting autoreactive B cells and suppressing humoral autoimmunity.
drug_name
Relma-cel (relmacabtagene autoleucel)
nct_id_drug_ref
NCT06297408